Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
TUSTIN, Calif., Dec. 03, 2015 (GLOBE NEWSWIRE) -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company focused on developing therapeutics to stimulate the body's immune system to fight cancer, today announced that it will report financial results for the second quarter of fiscal year 2016 ended October 31, 2015 on December 10, 2015 after market and will host a conference call and webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Peregrine's senior management will discuss financial results for the second quarter and review the recent progress of its clinical development programs.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.
To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a pipeline of novel drug candidates in clinical trials focused on the treatment of cancer. The company's lead immunotherapy candidate, bavituximab, is in Phase III development for the treatment of previously treated non-small cell lung cancer (the "SUNRISE trial") along with several investigator-sponsored trials evaluating other treatment combinations and additional oncology indications. Peregrine also has in-house cGMP manufacturing capabilities through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. For more information, please visit www.peregrineinc.com.
Contacts: Jay Carlson Peregrine Pharmaceuticals, Inc. (800) 987-8256 [email protected] Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
